Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
Public ClinicalTrials.gov record NCT01006265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Study identification
- NCT ID
- NCT01006265
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 464 participants
Conditions and interventions
Conditions
Interventions
- ACT-128800 Dose 1 Drug
- Placebo Drug
- ACT-128800 Dose 2 Drug
- ACT-128800 Dose 3 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2009 (Actual)
- Primary completion
- Jun 1, 2011 (Actual)
- Completion
- Jul 1, 2011 (Actual)
- Last update posted
- Mar 30, 2025
2009 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Investigative Site 3132 | Scottsdale | Arizona | 85259 | — |
| Clinical Investigative Site 3100 | Tucson | Arizona | 85741 | — |
| Clinical Investigative Site 3115 | Sacramento | California | 95817 | — |
| Clinical Investigative Site 3117 | Stanford | California | 94305 | — |
| Clinical Invesigative Site 3116 | Sarasota | Florida | 34233 | — |
| Clinical Investigative Site 3101 | Indianapolis | Indiana | 46202 | — |
| Clinical Investigative Site 3105 | Kansas City | Kansas | 66160 | — |
| Clinical Investigative Site 3107 | Lenexa | Kansas | 66214 | — |
| Clinical Investigative Site 3118 | Baltimore | Maryland | 21201 | — |
| Clinical Investigative Site 3133 | Worcester | Massachusetts | 01605 | — |
| Clinical Investigator 3136 | St Louis | Missouri | 63100 | — |
| Clinical Investigative Site # 3135 | Newark | New Jersey | 07103 | — |
| Clinical Investigative Site 3129 | Latham | New York | 12110 | — |
| Clinical Investigative Site # 3128 | New York | New York | 10032 | — |
| Clinical Investigative Site 3127 | Schenectady | New York | 12308 | — |
| Clinical Investigative Site 3120 | Stony Brook | New York | 11794 | — |
| Clinical Investigative Site 3119 | Raleigh | North Carolina | 27607 | — |
| Clinical Investigator 3126 | Akron | Ohio | 44320 | — |
| Clinical Investigative Site 3113 | Cincinnati | Ohio | 45219 | — |
| Clinical Investigative Site 3130 | Columbus | Ohio | 43221 | — |
| Clinical Investigator 3104 | Portland | Oregon | 97225 | — |
| Clinical Investigative Site 3125 | Philadelphia | Pennsylvania | 19107 | — |
| Clinical Investigative Site 3112 | Burlington | Vermont | 05401 | — |
| Clinical Investigative Site 3111 | Richmond | Virginia | 23298 | — |
| Clinical Investigative Site 3102 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01006265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01006265 live on ClinicalTrials.gov.